Cardiff Oncology Inc Aktie News

Cardiff Oncology (CRDF) remains a single-asset biotech, with its thesis reliant on onvansertib targeting PLK1 in difficult-to-treat cancers. Recent phase 2 CRDF-004 data showed diminished response rates for onvansertib versus earlier readouts, though both doses outperformed control. Cash runway extends into Q1 2027, but future large-scale trials will likely require significant additional funding.

SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that clinical data from an investigator-sponsored trial with onvansertib in chronic myelomonocytic leukemia (CMML) will be presented in a poster presentation at the 67th America...

SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and host one-on-one meetings at Sidoti's Year-End Virtual Investor Conference, which is taking place from December 10-11, 2025.

Cardiff Oncology Aktie: Entscheidungstag naht!

SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a fireside chat and 1x1 investor meetings at the Piper Sandler 37th Annual Healthcare Conference, which is taking place from December...

– Announced positive data from the ongoing Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer – – Expects to report an update from the Phase 2 CRDF-004 trial in Q1 2026 – – Cash and investments of $60.6 million as of September 30, 2025, projected runway into Q1 2027 – SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE)...

SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in two upcoming investor conferences in November 2025.

Cardiff Oncology is a speculative buy, driven by the potential of onvansertib as a first-in-class PLK1 inhibitor for first-line RAS-mutated mCRC. CRDF's Q1 2026 data readout for onvansertib is a pivotal catalyst, with positive results potentially unlocking blockbuster sales and significant share price appreciation. Key risks include clinical trial execution, capital needs, and heavy reliance on...